Besides, numerous RCTs have acknowledged the cardiovascular benefits and weight loss properties of GLP-1 agonists in patients with T2DM, which were not evident for DPP-4 inhibitors.25 The gene discussed is DPP4; the disease is type 2 diabetes mellitus.